|
|
|
| Clinical Research of Milrinone in Treatment to Refractory Heart Failure |
| People’s Hospital of Dongguan City， Dongguan 523000， China |
|
|
|
|
Abstract Objective： To investigate the effectiveness and safety of milrinone in treatment to refractory heart failure. Method： During January 2012 to June 2014， 60 patients with refractory heart failure were divided into sodium nitroprusside group（ n=30） and milrinone group（n=30）. The dosage of sodium nitroprusside and milrinone were 0.5-3 μg/（kg·min）min and 0.5 μg/（kg·min）， which the time of duration was 3 days. Result： 28 patients in sodium nitroprusside group and 25 patients in milrinone group were included in the analysis. 7-day effectiveness of the milrinone group was significantly higher than that of the sodium nitroprusside group（ P<0.05）. BNP of the milrinone group after
treatment was significantly lower than that of the sodium nitroprusside group（ P<0.05）. There were significant differences in LVEF， E/A， SV， CI between the two groups（ P<0.05）. There was no significant difference in incidence of adverse events between the two groups. Conclusion： Milrinone can improve the success rate of rescue in patients with Refractory heart failure.
|
|
|
|
|
|
|
|
|
